Anadis is a biotechnology company based in Melbourne, Australia that trades on the Australian Stock Exchange with the symbol IMC.[1] an ADR Level I program was initiated in late 2007, and the company is quoted over the counter in the U.S. with the ticker ANDIY
The company focused on antigen-primed, dairy-derived health products. Anadis’ proprietary, technology enables it to rapidly develop polyclonal antibody and other proteins-based solutions to a range of important diseases.[citation needed] The all-natural bovine colostrum-derived platform, its regulatory classification as GRAS (Generally Regarded as Safe) when administered orally and the proprietary methods of manufacturing, allows for short time-frame from bench to market with high manufacturing scalability.
With expertise in research, commercialisation and manufacturing[citation needed] Anadis specialises in innovative nutraceutical, pharmaceutical and related therapeutic technology products, including Oral and GI Mucositis, Routine and Avian Influenza, - E. coli Travellers' Diarrhoea (TD), Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), and Anthrax containment.
[edit] External links
- [www.immuron.com.au Official website]
[edit] References
- ^ "Anadis". Australian Stock Exchange. 2007-06-05. http://www.asx.com.au/asx/markets/PriceResults.jsp?method=get&template=F1001&ASXCodes=IMC.
